Andrew Baum

Stock Analyst at Citigroup

(2.84)
# 1,870
Out of 4,911 analysts
63
Total ratings
72.09%
Success rate
12.83%
Average return

Stocks Rated by Andrew Baum

Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115$84
Current: $84.71
Upside: -0.84%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30$29
Current: $24.79
Upside: +16.98%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60$65
Current: $48.43
Upside: +34.21%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60$40
Current: $36.67
Upside: +9.08%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170$215
Current: $190.28
Upside: +12.99%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675$895
Current: $812.69
Upside: +10.13%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5$10
Current: $9.61
Upside: +4.06%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $37.97
Upside: -